Cullinan Therapeutics (CGEM) Shares Outstanding (2020 - 2026)

Cullinan Therapeutics' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $61.5 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 4.69% year-over-year to $61.5 million; the TTM figure through Mar 2026 stood at $61.5 million (up 4.69% YoY), while the FY2025 annual figure was $60.2 million, up 2.96% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $61.5 million, up from $60.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $61.5 million in Q1 2026, with the low at $39.3 million in Q1 2023.
• The 5-year median for Shares Outstanding (Entity) is $45.8 million (2022), against an average of $50.9 million.
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) fell 11.9% in 2023, then soared 36.39% in 2024.
• Cullinan Therapeutics' Shares Outstanding (Entity) stood at $45.8 million in 2022, then fell by 6.32% to $42.9 million in 2023, then jumped by 36.39% to $58.5 million in 2024, then grew by 2.96% to $60.2 million in 2025, then grew by 2.0% to $61.5 million in 2026.
• Business Quant data shows CGEM's Shares Outstanding (Entity) at $61.5 million in Q1 2026, $60.2 million in Q4 2025, and $59.1 million in Q3 2025.